A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT07029399
This study is recruiting at 18 US sites in 15 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include: What is the recommended dose for expansion and/or Phase 2, for both monotherapy and in combination with ET What medical issues/symptoms do participants experience when taking NKT5097 as monotherapy as well as in combination with ET
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- HR+ Breast Cancer
- Triple Negative Breast Cancer (TNBC)
- CCNE1 Amplified Advanced Solid Tumors
- HR+ HER2- Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- NiKang Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- August 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- City of Hope · Duarte, CA
- UC San Diego Moores Cancer Center · La Jolla, CA
Colorado · 1
- Sarah Cannon Research Institute at HealthONE · Denver, CO
Connecticut · 1
- Yale Cancer Center · New Haven, CT
Florida · 1
- SCRI Florida Cancer Specialists - Sarasota · Sarasota, FL
Iowa · 1
- University of Iowa · Iowa City, IA
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Michigan · 1
- South Texas Accelerated Research Therapeutics (START) Midwest · Grand Rapids, MI
Missouri · 1
- Washington University · St Louis, MO
Nevada · 1
- Comprehensive Cancer Centers of Nevada · Las Vegas, NV
Ohio · 1
- Cleveland Clinic · Cleveland, OH
Pennsylvania · 1
- UPMC Hillman Cancer Center · Pittsburgh, PA
Texas · 3
- University of Texas Southwestern Medical Center · Dallas, TX
- MD Anderson Cancer Center · Houston, TX
- South Texas Accelerated Research Therapeutics (START) San Antonio · San Antonio, TX
Utah · 1
- South Texas Accelerated Research Therapeutics (START) Mountain Region · West Valley City, UT
Virginia · 1
- NEXT Virginia · Fairfax, VA
West Virginia · 1
- West Virginia University · Morgantown, WV
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.